Focused On-demand Library for Dolichol-phosphate mannosyltransferase subunit 1

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
O60762

UPID:
DPM1_HUMAN

ALTERNATIVE NAMES:
Dolichol-phosphate mannose synthase subunit 1; Dolichyl-phosphate beta-D-mannosyltransferase subunit 1; Mannose-P-dolichol synthase subunit 1

ALTERNATIVE UPACC:
O60762; O15157; Q6IB78; Q96HK0

BACKGROUND:
Dolichyl-phosphate beta-D-mannosyltransferase subunit 1 is a catalytic subunit of the dolichol-phosphate mannose (DPM) synthase complex. Its function in transferring mannose to dolichol monophosphate for the synthesis of dolichol phosphate mannose underpins its crucial role in protein glycosylation pathways. These pathways are vital for embryonic development, differentiation, and maintenance of cell functions, reflecting the protein's broad biological significance.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in the pathogenesis of Congenital disorder of glycosylation 1E, a disorder affecting glycoprotein biosynthesis, Dolichyl-phosphate beta-D-mannosyltransferase subunit 1 represents a promising target for therapeutic intervention. Exploring its function further could lead to novel treatments for the diverse clinical manifestations associated with this congenital disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.